Medical and Healthcare Sector Sees Active Investment with $1.27 Billion Raised Last Week

　　【Pharmaceutical Network Industry DynamicsLast week, the medical and health sector saw active investment and financing, with a total financing amount of approximately 920 million yuan, involving at least 11 pharmaceutical companies including TenNor Therapeutics, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., TONGSHU GENE, and iRegene.
 

From the disclosed pharmaceutical companies' financing amounts, TenNor Therapeutics ranks prominently. The company announced on October 16 the completion of the first closing of an over 300 million RMB Series E financing round. This round was co-led by Zhongshan Venture Capital, under Zhongshan Investment Holdings, and the AMR Action Fund (AMR Fund). The funds will be used to support the core new drug R&D pipeline, including late-stage clinical trials and commercialization of TNP-2198, a new drug candidate for treating Helicobacter pylori infections, and TNP-2092, a new drug candidate for treating infections related to implanted medical devices. It is reported that the company is committed to addressing the dual challenges of bacterial resistance and tolerance, providing solutions for bacterial infections and microbiota metabolism-related diseases that currently lack effective treatment options.
 

Following this, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. announced on October 18 the completion of a CNY 300 million Series C1 financing round. This round was led by China Biologic Products, with participation from Pudong Venture Capital and Zhangjiang Haoheng, and follow-on investments from Qiming Venture Partners and Shanghai BioPharmaceutical Fund. Additionally, Lixin Pharmaceutical has recently initiated its Series C2 financing. The proceeds will primarily be used to accelerate the clinical development of the company’s pipeline, especially LM-302 and LM-108, and to support its self-developed antibody discovery platform, next-generation ADC technology platform, and bispecific antibody technology platform, continuously delivering an innovative pipeline with international competitiveness.
 

According to reports, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. focuses on the development of tumor-specific targeted ADCs and immune-modulating macromolecule innovative drugs. It has established a comprehensive pipeline of differentiated innovative drugs with independent intellectual property rights and global competitiveness, covering all stages from preclinical to Phase III clinical trials. Currently, the company has successfully advanced multiple innovative drug projects to the forefront of global clinical stages. Among them, LM-302 has entered Phase III registrational clinical trials in China; LM-108 is in Phase II clinical trials; LM-101, LM-305, LM-299, and LM-24C5 are all in Phase I clinical trials. Through continuous innovation and strategic cooperation, the company is accelerating the advancement of its product pipeline for the benefit of patients worldwide.
 

In addition, TONGSHU GENE and iRegene have both raised over 100 million yuan in financing. Among them, TONGSHU GENE, a gene testing company, has officially completed its D-round financing of over 100 million yuan. This round of financing was led by Wuxi Liangxi Science and Innovation Industry Investment Fund, with Jiangsu Jiandao Venture Capital Co., Ltd. participating. The funds raised in this round will mainly be used for the company to continue strengthening R&D investment, expanding production scale, exploring market channels, and enhancing brand influence.
 

iRegene Announces Over 100 Million Yuan in Series B FinancingiRegene, a cell therapy drug company, has announced the completion of an over 100 million yuan Series B financing round. This round was jointly led by Ceyuan Capital and Guosheng Capital, with participation from relevant industry investment institutions and Wuhan Optics Valley Industrial Investment. EasySea Capital served as the exclusive financial advisor to iRegene in this financing round. Additionally, the company's Series B+ financing is nearing its final stages and is expected to close soon. The proceeds from this financing will be used to accelerate the clinical advancement of the company’s Parkinson’s disease treatment products NouvNeu001/NouvNeu003 and ophthalmic treatment product NouvSight001 in both China and the United States. The funds will also support the development of multiple innovative pipelines and enhance the company’s clinical capabilities, as well as strengthen its industrialization efforts.
 

Active Investment and Financing in the Healthcare Sector Indicates Strong Confidence in the Industry's Future Development. According to a research report by GF Securities, the pharmaceuticals sector's overall valuation is at a historic low, with fundamentals showing mild improvement. A market pullback presents an important window to seize investment opportunities in the pharmaceuticals sector, with particular optimism for innovative drugs, medical services and aesthetics, medical devices, and traditional Chinese medicine segments.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.